Gut bacteria swap explored as MS treatment in early trial
NCT ID NCT03594487
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether a fecal transplant from a healthy donor could be safe and affect the immune system in people with relapsing-remitting multiple sclerosis. Only 5 participants were enrolled before the study was stopped. The goal was to see if changing gut bacteria might help control the disease, but results are limited due to the small size and early termination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSF Multiple Sclerosis Center
San Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sensing wrist position unlock better hand control in MS?
- AI-Powered tool aims to sharpen MS treatment choices
- Walking and thinking at the same time may reveal hidden MS balance issues
- MS balance breakthrough? scientists probe Spine's role
- Nurse-Led video calls aim to empower MS patients
- Spinal lesions in early MS may signal future mobility trouble